JOSEPHINE DEGUZMAN: Open Payments
NPI 1043391675 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$32,308 in 129 payments from 9 companies in 2025. Trend: 2023 $1,238 · 2024 $1,499 · 2025 $32,308
Speaker / faculty: $27,160Travel & lodging: $2,529Food & beverage: $2,159Consulting: $460
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 45 | $31,076 |
| Alkermes, Inc. | 22 | $400 |
| Neurocrine BioSciences, Inc. | 22 | $229 |
| Lundbeck LLC | 10 | $192 |
| Vanda Pharmaceuticals Inc. | 9 | $143 |
| Janssen Pharmaceuticals, Inc | 13 | $136 |
| E.R. Squibb & Sons, L.L.C. | 4 | $70 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $31 |
Products named: UZEDY, AUSTEDO XR, ARISTADA, INGREZZA, ABILIFY ASIMTUFII, FANAPT, INVEGA SUSTENNA, COBENFY.
Industry payments across OK — which companies pay providers there.
